Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun.

Area of Science:

• Biochemistry
• Structural Biology
• Molecular Oncology

Background:

• The oncogenic transcription factor activator protein-1 (AP-1) is crucial for cell proliferation and is formed by Fos and Jun protein dimerization.
• The proto-oncogene cFos protein's structure and function are key targets for cancer research.

Purpose of the Study:

• To design and characterize smaller, constrained peptides derived from cFos that enhance binding to Jun.
• To evaluate the therapeutic potential of these peptides in inhibiting cancer cell proliferation.

Main Methods:

• X-ray crystallography to determine the structure of a Fos-derived peptide bound to Jun.
• Circular dichroism spectroscopy to assess peptide structural integrity.
• Isothermal titration calorimetry to measure binding thermodynamics.
• Cell-based assays to evaluate peptide uptake, nuclear localization, and anti-proliferative effects.

Main Results:

• A 37-residue Fos-derived peptide (FosW) structure bound to Jun was determined.
• Iterative downsizing yielded a 25-residue constrained peptide with enhanced helical stability and Jun-binding affinity.
• This shorter peptide retained 80% of the binding free energy compared to the larger FosW peptide.
• The constrained peptide, when conjugated with cell-penetrating and nuclear localization signals, effectively inhibited breast cancer cell proliferation.

Conclusions:

• Constrained peptides can mimic and enhance the function of larger proteins like cFos.
• Downsized, helix-constrained peptides represent a promising strategy for developing targeted cancer therapeutics.
• The developed peptide demonstrates potential for inhibiting cancer cell growth through nuclear targeting.